SCHEMBL2644589

SCHEMBL2644589

CN(C)C(=O)c1ccc(Oc2cc(C(=O)O)cc3c2CC(C)(CO)O3)cc1F

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GCK P35557 4/20 0.54
LPAR1 Q92633 5/20 0.39
LPAR5 Q9H1C0 5/20 0.39
FFAR1 O14842 1/20 0.32
S1PR2 O95136 1/20 0.32
EZH2 Q15910 1/20 0.32
RXRA P19793 2/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
HIF1A Q16665 1/20 0.31
F10 P00742 2/20 0.31
RARA P10276 1/20 0.31
RARB P10826 1/20 0.31
RARG P13631 1/20 0.31
F2 P00734 1/20 0.31
FFAR4 Q5NUL3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2644770 0.91 GCK (0.46) GCKLPAR1LPAR5FFAR1EZH2
SCHEMBL644290 0.89 GCK (0.51) GCKLPAR1LPAR5HIF1A
SCHEMBL644377 0.89 GCK (0.52) GCKLPAR1LPAR5FFAR1EZH2
SCHEMBL2644922 0.85 GCK (0.72) GCKS1PR2
SCHEMBL2643802 0.84 GCK (0.48) GCKLPAR1LPAR5EZH2RXRA
SCHEMBL645237 0.83 GCK (0.71) GCK
SCHEMBL645334 0.83 GCK (0.78) GCKF10
SCHEMBL2644367 0.83 GCK (0.51) GCK
SCHEMBL645314 0.81 GCK (0.43) GCKLPAR1LPAR5HIF1A
SCHEMBL2643750 0.80 GCK (0.49) GCKLPAR1LPAR5EZH2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
EP-2010520-B1 HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PROD INC (US) 2012-09-12 EP disclosed
EP-2463283-A1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases Pfizer Products Inc. (US) 2012-06-13 EP disclosed
US-7842713-B2 Fused phenyl amido heterocyclic compounds PFIZER INC (US) 2010-11-30 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 GCK 1/4885LPAR1 3626/4885LPAR5 4019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.